Baker BROS. Advisors LP Sells 1,720,466 Shares of Sana Biotechnology, Inc. $SANA

Baker BROS. Advisors LP lessened its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 84.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 310,483 shares of the company’s stock after selling 1,720,466 shares during the quarter. Baker BROS. Advisors LP owned about 0.12% of Sana Biotechnology worth $1,264,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SANA. Mercer Global Advisors Inc. ADV acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth about $36,000. Russell Investments Group Ltd. acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth about $39,000. LRI Investments LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth about $41,000. Jacobi Capital Management LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth about $41,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock worth $42,000 after purchasing an additional 4,931 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Up 7.4%

Sana Biotechnology stock opened at $3.04 on Thursday. The business has a 50 day moving average price of $3.20 and a two-hundred day moving average price of $3.77. The stock has a market cap of $846.00 million, a price-to-earnings ratio of -3.27 and a beta of 2.14. Sana Biotechnology, Inc. has a 12 month low of $2.58 and a 12 month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SANA has been the subject of several research analyst reports. Rodman & Renshaw initiated coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. HC Wainwright cut their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Sunday, June 7th. Finally, Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.